Table 2.
Genotype | Period (hr) | Power | %Rhythmic | N |
---|---|---|---|---|
UASMAN1RNAi | 24.4 ± 0.1 | 110 ± 10 | 100 | 14 |
UASMAN1RNAi;cryGAL4-39/+; UASdcr2/+ | 26.3 ± 0.3*,† | 29 ± 6*,† | 80 | 15 |
UASMAN1RNAi; UASdcr2/+;cryGAL4-16/+ | 27.9 ± 0.4*,† | 39 ± 8*,† | 69 | 16 |
UASLamRNAi/+ | 23.6 ± 0.1 | 129 ± 12 | 100 | 16 |
cryGAL4-39/+; UASLamRNAi/UASdcr2 | 25.1 ± 0.4* | 26 ± 17*,† | 50 | 14 |
UASLamRNAi/UASdcr2; cryGAL4-16/+ | 26.8 ± 0.1*,† | 126 ± 17 | 100 | 13 |
UASLBRRNAi/+ | 23.5 ± 0.0 | 112 ± 14 | 100 | 15 |
cryGAL4-39/UASLBRRNAi; UASdcr2/+ | 24.9 ± 0.1 | 61 ± 12* | 80 | 15 |
UASLBRRNAi/UASdcr2; cryGAL4-16/+ | 24.6 ± 1.7 | 12 ± 4*,† | 44 | 16 |
cryGAL4-39/+; UASdcr2/+ | 24.9 ± 0.1 | 69 ± 12 | 88 | 16 |
UASdcr2/+;cryGAL4-16/+ | 26.1 ± 0.1 | 87 ± 10 | 94 | 16 |
One-way ANOVA compared to UASRNAi control lines, p < 0.05.
One-way ANOVA compared to control lines with GAL4 and UASdcr2, p < 0.05.
dicer2 (dcr2) is co-expressed to enhance the effects of RNAi.